Vor Biopharma Inc
NASDAQ:VOR
Intrinsic Value
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. [ Read More ]
The intrinsic value of one VOR stock under the Base Case scenario is 2.01 USD. Compared to the current market price of 1.73 USD, Vor Biopharma Inc is Undervalued by 14%.
Valuation Backtest
Vor Biopharma Inc
Run backtest to discover the historical profit from buying and selling VOR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Vor Biopharma Inc
Current Assets | 140.8m |
Cash & Short-Term Investments | 137.2m |
Other Current Assets | 3.6m |
Non-Current Assets | 57.3m |
PP&E | 50.1m |
Other Non-Current Assets | 7.2m |
Current Liabilities | 15.6m |
Accounts Payable | 815k |
Accrued Liabilities | 14.7m |
Other Current Liabilities | 50k |
Non-Current Liabilities | 31.8m |
Other Non-Current Liabilities | 31.8m |
Earnings Waterfall
Vor Biopharma Inc
Revenue
|
0
USD
|
Operating Expenses
|
-126m
USD
|
Operating Income
|
-126m
USD
|
Other Expenses
|
8.2m
USD
|
Net Income
|
-117.9m
USD
|
Free Cash Flow Analysis
Vor Biopharma Inc
What is Free Cash Flow?
VOR Profitability Score
Profitability Due Diligence
Vor Biopharma Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Vor Biopharma Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
VOR Solvency Score
Solvency Due Diligence
Vor Biopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Vor Biopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VOR Price Targets Summary
Vor Biopharma Inc
Ownership
VOR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
VOR Price
Vor Biopharma Inc
Average Annual Return | -38.4% |
Standard Deviation of Annual Returns | 8.96% |
Max Drawdown | -97% |
Market Capitalization | 117.5m USD |
Shares Outstanding | 68 215 800 |
Percentage of Shares Shorted | 10.62% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 135 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. VOR33 is the lead product candidate consisting of genome-edited hematopoietic stem and progenitor cells that have been engineered to lack the CD33 protein. The company is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of VOR33 in participants with AML. The company offers VCAR33 programs that are chimeric antigen receptor T (CAR-T) cell therapy candidates designed to target CD33.
Contact
IPO
Employees
Officers
The intrinsic value of one VOR stock under the Base Case scenario is 2.01 USD.
Compared to the current market price of 1.73 USD, Vor Biopharma Inc is Undervalued by 14%.